Complete financial analysis of Neumora Therapeutics, Inc. Common Stock (NMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neumora Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- OPNET Technologies Co., Ltd. (8034.TWO) Income Statement Analysis – Financial Results
- Eurobank Ergasias Services and Holdings S.A. (EGFEF) Income Statement Analysis – Financial Results
- Openn Negotiation Limited (OPN.AX) Income Statement Analysis – Financial Results
- Pearl Holdings Acquisition Corp (PRLH) Income Statement Analysis – Financial Results
- Plymouth Industrial REIT, Inc. (PLYM) Income Statement Analysis – Financial Results
Neumora Therapeutics, Inc. Common Stock (NMRA)
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 668.00K | 2.70M | 1.55M | 0.00 |
| Gross Profit | -668.00K | -2.70M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.72M | 104.75M | 212.78M | 87.13M |
| General & Administrative | 45.48M | 31.12M | 24.55M | 8.39M |
| Selling & Marketing | -668.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 44.81M | 31.12M | 24.55M | 8.39M |
| Other Expenses | 0.00 | 405.00K | 11.00K | -3.75M |
| Operating Expenses | 187.53M | 135.87M | 237.32M | 95.52M |
| Cost & Expenses | 188.19M | 135.87M | 237.32M | 95.52M |
| Interest Income | 16.61M | 4.56M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 668.00K | 2.70M | 1.55M | 105.00K |
| EBITDA | -187.53M | -135.28M | -236.79M | -95.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -188.19M | -135.87M | -237.32M | -95.52M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -47.46M | 4.97M | 11.00K | -3.75M |
| Income Before Tax | -235.66M | -130.90M | -237.31M | -99.27M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 268.00K | -4.56M | 301.44K | -101.30K |
| Net Income | -235.93M | -130.90M | -237.31M | -99.27M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -0.86 | -1.56 | -0.65 |
| EPS Diluted | -1.49 | -0.86 | -1.56 | -0.65 |
| Weighted Avg Shares Out | 158.83M | 151.95M | 151.95M | 151.95M |
| Weighted Avg Shares Out (Dil) | 158.83M | 151.95M | 151.95M | 151.95M |
Neumora Therapeutics Announces Pricing of Initial Public Offering
IPO Update: Neumora Therapeutics Seeks $250 Million U.S. IPO
Source: https://incomestatements.info
Category: Stock Reports